Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Peptide Competition: Extracts prepared from 293T cells left unstimulated (1) or stimulated with HGF (2-5) were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4°C
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Dog, Virus, Hamster, Mouse, Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human c-Met that contains tyrosines 1230, 1234 and 1235. The sequence is conserved in mouse and rat.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The c-Met oncogene was originally isolated from a chemical carcinogen-treated human osteogenic sarcoma cell line by transfection analysis in NIH/3T3 cells. The Met proto-oncogene product was identified as a trans-membrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. The c-Met gene product has been identified as the cell surface receptor for hepatocyte growth factor, a plasminogen-like protein thought to be a humoral mediator of liver regeneration.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Spatially restricted Hedgehog signalling regulates HGF-induced branching of the adult prostate.
44-888G was used in western blot to investigate the mechanisms underlying the specification of branch location
|Lim A,Shin K,Zhao C,Kawano S,Beachy PA||Nature cell biology (16:1135)||2014|
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
44-888G was used in western blot to discuss the use of LY280653 in both preclinical in vitro and in vivo non-small cell lung cancer models.
|Wu W,Bi C,Credille KM,Manro JR,Peek VL,Donoho GP,Yan L,Wijsman JA,Yan SB,Walgren RA||Clinical cancer research : an official journal of the American Association for Cancer Research (19:5699)||2013|
Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer.
44-888G was used in western blot to compare multiplexed quantum dot labeling with other techniques to identify prostate cancer.
|Hu P,Chu GC,Zhu G,Yang H,Luthringer D,Prins G,Habib F,Wang Y,Wang R,Chung LW,Zhau HE||PloS one (6:null)||2011|
|Human||1:500||Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines.||Levin VA,Panchabhai SC,Shen L,Kornblau SM,Qiu Y,Baggerly KA||Journal of proteome research (9:179)||2010|
|Human||Not Cited||Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis.||Bogatkevich GS,Ludwicka-Bradley A,Highland KB,Hant F,Nietert PJ,Singleton CB,Feghali-Bostwick CA,Silver RM||Arthritis and rheumatism (56:2432)||2007|
|Mouse||Not Cited||Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys.||Mizuno S,Nakamura T||The American journal of pathology (166:1895)||2005|
|Human||Not Cited||Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.||Ma PC,Jagadeeswaran R,Jagadeesh S,Tretiakova MS,Nallasura V,Fox EA,Hansen M,Schaefer E,Naoki K,Lader A,Richards W,Sugarbaker D,Husain AN,Christensen JG,Salgia R||Cancer research (65:1479)||2005|
|A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.||Christensen JG,Schreck R,Burrows J,Kuruganti P,Chan E,Le P,Chen J,Wang X,Ruslim L,Blake R,Lipson KE,Ramphal J,Do S,Cui JJ,Cherrington JM,Mendel DB||Cancer research (63:7345)||2003|
|Virus||Not Cited||Different susceptibility of human mesothelial cells to polyomavirus infection and malignant transformation.||Carbone M,Burck C,Rdzanek M,Rudzinski J,Cutrone R,Bocchetta M||Cancer research (63:6125)||2003|
|Mouse||Not Cited||A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.||Sattler M,Pride YB,Ma P,Gramlich JL,Chu SC,Quinnan LA,Shirazian S,Liang C,Podar K,Christensen JG,Salgia R||Cancer research (63:5462)||2003|
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
44-888G was used in immunohistochemistry (paraffin) to study the biochemical activity of cabozantiinib against disease-associated RET mutants and its growth inhibitory activity in medullary thyroid cancer models.
|Bentzien F,Zuzow M,Heald N,Gibson A,Shi Y,Goon L,Yu P,Engst S,Zhang W,Huang D,Zhao L,Vysotskaia V,Chu F,Bautista R,Cancilla B,Lamb P,Joly AH,Yakes FM||Thyroid : official journal of the American Thyroid Association (23:1569)||2013|
Preservations of nephrin and synaptopodin by recombinant hepatocyte growth factor in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice.
44-888G was used in immunohistochemistry - paraffin section to investigate the effect of hepatocyte growth factor on nephrin and synaptopodin expression.
|Kato T,Mizuno S,Nakamura T||Nephrology (Carlton, Vic.) (16:310)||2011|
|Mouse||Not Cited||Hepatocyte growth factor contributes to fracture repair by upregulating the expression of BMP receptors.||Imai Y,Terai H,Nomura-Furuwatari C,Mizuno S,Matsumoto K,Nakamura T,Takaoka K||Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (20:1723)||2005|
c-met; EC 126.96.36.199; hepatocyte growth factor receptor; Hepatocyte growth factor receptor precursor; HGF receptor; HGF-SF receptor; HGF/SF receptor; kinase EC 188.8.131.52; Met proto- oncogene tyros; Met proto- oncogene tyrosine kinase; met proto-oncogene tyrosine kinase; proto-oncogene c-Met; scatter factor receptor; SF receptor; tyrosine-protein kinase Met
AI838057; AUTS9; c-Met; DFNB97; HGF; HGFR; MET; Par4; RCCP2